Catalent Inc (NYSE:CTLT)
| 102.70 BATS BZX Real-Time Price As of 11:53am ET |  +2.22 / +2.21%Today’s Change | 67.97 Today|||52-Week Range 127.68 | -1.32% Year-to-Date |
Latest CTLT News | Press Releases
| Minerva (NERV) Soars on Promising Schizophrenia Study Data May 12 / Zacks.com - Paid Partner Content | Catalent Inc (CTLT) Q3 2021 Earnings Call Transcript May 04 / MotleyFool.com - Paid Partner Content |
| Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? May 07 / Zacks.com - Paid Partner Content | Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates May 04 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 100.48 |
| Today’s open | 101.00 |
| Day’s range | 100.45 - 102.74 |
| Volume | 210,595 |
| Average volume (3 months) | 1,071,637 |
| Market cap | $18.3B |
Data as of 11:53am ET, 05/14/2021
Growth & Valuation
| Earnings growth (last year) | +26.20% |
| Earnings growth (this year) | +35.22% |
| Earnings growth (next 5 years) | +20.92% |
| Revenue growth (last year) | +22.89% |
| P/E ratio | 34.1 |
| Price/Sales | 3.61 |
| Price/Book | 6.04 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| INCYIncyte Corp | +0.25 | +0.30% |
| VTRSViatris Inc | -0.11 | -0.69% |
| HZNPHorizon Therapeutics... | +3.67 | +4.18% |
| ALNYAlnylam Pharmaceutic... | +2.96 | +2.22% |
Data as of 11:52am ET, 05/14/2021
Financials
| Next reporting date | August 30, 2021 |
| EPS forecast (this quarter) | $1.10 |
| Annual revenue (last year) | $3.1B |
| Annual profit (last year) | $173.0M |
| Net profit margin | 5.59% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Somerset, New Jersey |
Forecasts
